TL;DR
Get beauty and skincare favorites delivered free — and shop member deals
- Fast, free delivery on millions of items
- Access to Prime Big Deal Days deals on October 6–7
- Prime Video, Amazon Music and more included
Amorepacific Ventures has invested in biotechnology company Junevity and signed a separate licensing agreement covering cosmetic applications of Junevity’s RESET Platform. The companies plan to research skin-ageing pathways for potential cosmetic products; Amorepacific will lead product development and commercialisation. No product, launch date or investment amount was disclosed in the source report.
Amorepacific Ventures, the corporate investment arm of the South Korean beauty group behind Laneige, has invested in biotechnology company Junevity and signed a separate licensing agreement for cosmetic applications of Junevity’s technology. The companies say they will research skin-ageing pathways that could inform future cosmetics, with Amorepacific responsible for product development and commercialisation.
The collaboration will use Junevity’s RESET Platform to investigate biological pathways involved in skin ageing and identify targets that may be suitable for cosmetic applications. The companies plan to combine Junevity’s target-discovery capabilities with Amorepacific’s skin biology expertise, cosmetic development experience and routes to market. Their stated aim is to explore approaches that could reset or rejuvenate skin gene networks toward what they describe as a healthier state.
The investment and licensing agreement are related but distinct parts of the arrangement: Amorepacific Ventures made the strategic investment, while the agreement grants a basis for work on cosmetic field applications. According to the report, Amorepacific will lead the development and sale of any resulting cosmetic products. Junevity will continue advancing therapeutic applications of its platform, so the announced collaboration does not replace or describe its separate drug-development work.
Neither company disclosed the investment amount, detailed licensing terms, research timetable or a product launch plan in the source report. The announcement concerns research and development, not a finished skincare product or evidence that a specific cosmetic treatment has been shown to change skin ageing.
From Biotech Research to Skincare
The deal connects a biotechnology platform focused on discovering biological targets with a beauty company that can develop and market consumer products. For Amorepacific, the research could provide new directions for skin-ageing science and future product development. For Junevity, the licensing arrangement creates a route to test whether its platform has applications beyond its therapeutic pipeline.
The commercial significance remains prospective. Any cosmetic products would depend on what the research identifies, whether the findings can be translated into suitable formulations, and how those products perform under appropriate testing. The announcement does not establish that gene-network approaches will produce a particular consumer benefit, nor does it name products or set a launch date. Readers should understand “skin longevity” and “rejuvenation” here as the companies’ research aims, not as proven outcomes.
As an affiliate, we earn on qualifying purchases.
A Separate Cosmetic Research Track
Junevity describes its RESET Platform as a target-discovery engine. In this collaboration, the stated focus is on skin biology and cosmetic applications, with research into pathways associated with ageing. The source report does not provide technical details about how the platform identifies targets, what testing will be used, or which specific pathways the partners will examine.
The agreement also sits alongside Junevity’s work on therapeutic applications. Junevity chief executive John Hoekman said the company’s lead small interfering RNA, or siRNA, candidate for obesity was headed into human clinical trials. That is a separate development in the company’s therapeutic pipeline, not a clinical programme for a skincare product and not evidence about the performance of the cosmetic collaboration.
Amorepacific’s role spans research input and the commercial side of the proposed work. Its expertise in skin biology and cosmetics is intended to complement Junevity’s discovery platform. The source report identifies Laneige as one of Amorepacific’s brands, but does not say that any eventual product will be sold under Laneige or another named brand.
““The next-generation of skin health innovations will be informed by deeper research-driven insights into the biology of skin ageing, particularly the role of gene networks and transcriptional regulation in longevity.””
— Brian Byung-Fhy Suh, CTO of Amorepacific R&I Center
As an affiliate, we earn on qualifying purchases.
Product and Research Details Pending
The announcement does not identify the specific skin-ageing pathways the partners will study, the research milestones or how success will be measured. It also gives no investment figure, licensing duration, exclusivity terms, development schedule or expected time to market. The source report does not name a product, formulation, brand or intended launch region.
It remains unclear what evidence would be required before a research finding becomes a cosmetic ingredient or finished product. No clinical or consumer-test results for this collaboration were reported, and the announcement does not show that the platform has already produced a cosmetic intervention with demonstrated effects on skin ageing. Further details would be needed to assess the research’s scope and any eventual product claims.
As an affiliate, we earn on qualifying purchases.
Research Before Any Product Launch
The next stated step is joint research into pathways that may be appropriate for cosmetic applications. Junevity is expected to contribute its RESET Platform, while Amorepacific will bring skin biology and cosmetic development expertise. If the work yields candidates the companies consider suitable, Amorepacific is set to lead their development and commercialisation under the agreement.
The companies have not announced public research milestones, a timetable or a first product. Further announcements would be needed to establish what the research identifies, whether a product moves into development, which brand might sell it and when it could reach consumers. Junevity’s therapeutic work, including the obesity siRNA candidate mentioned by its chief executive, will continue on a separate track.
As an affiliate, we earn on qualifying purchases.
Key Questions
What has Amorepacific announced?
Amorepacific Ventures invested in Junevity and the companies signed a separate licensing agreement covering cosmetic applications of Junevity’s RESET Platform. They plan to research skin-ageing pathways that could inform future cosmetics.
What is Junevity’s RESET Platform expected to do in the partnership?
The companies say the platform will be used to discover and investigate skin-ageing pathways that may be suitable for cosmetic applications. The source report does not provide technical detail about the platform’s methods or identify the pathways being studied.
Is a new skincare product available or scheduled?
No. The announcement describes a research collaboration, not a launched product. The source report gives no product name, brand, release date or development timetable.
Who would develop and sell any resulting cosmetics?
According to the source report, Amorepacific will lead cosmetic product development and commercialisation. The companies have not said which Amorepacific brand, if any, would carry a future product.
Is Junevity’s obesity drug work part of this skincare agreement?
No. Junevity’s lead siRNA candidate for obesity is part of its separate therapeutic pipeline. Its chief executive said the candidate was headed into human clinical trials; the source report does not give a trial date or results.
Source: rss
Halloween Picks
halloween
As an affiliate, we earn on qualifying purchases.
